Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 8,139 shares at $23.64 ($194K) on 2021-03-26, disclosed to the SEC on 2021-03-29.
Open-market sale of $194k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.64 | 3,389 | $80K | 41.4% |
| 2 | $23.64 | 3,389 | $80K | 41.4% |
| 3 | $24.48 | 1,361 | $33K | 17.2% |
| Total | $23.78 avg | 8,139 | $194K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |